Dr. Shah on the Future of CAR T-Cell Therapy in Multiple Myeloma

Video

Nina Shah, MD, discusses the future of CAR T-cell therapy in multiple myeloma. 

Nina Shah, MD, associate professor of medicine, Department of Medicine, at the University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center, discusses the future of CAR T-cell therapy in multiple myeloma. 

In July 2020, a biologics license application was resubmitted to the FDA for the BCMA-directed CAR T-cell therapy idecabtagene vicleucel (ide-cel; bb2121) for the treatment of patients with relapsed/refractory multiple myeloma. 

To date, most clinical trials evaluating CAR T-cell therapy have included patients who have heavily pretreated, relapsed/refractory disease, explains Shah. However, inclusion criteria ​typically require ​patients to have had 3 ​prior lines of treatment ​and have progressing disease.

​Although investigational agents in the pipeline could lead to ​novel combination regimens in the near future​, enrollment in clinical trials remains a critical option for patients, Shah concludes.

Recent Videos
Haydar Frangoul, MD, the medical director of pediatric hematology/oncology at Sarah Cannon Research Institute and Pediatric Transplant and Cellular Therapy Program at TriStar Centennial
David Barrett, JD, the chief executive officer of ASGCT
Georg Schett, MD, vice president research and chair of internal medicine at the University of Erlangen – Nuremberg
David Barrett, JD, the chief executive officer of ASGCT
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Caroline Diorio, MD, FRCPC, FAAP, an attending physician at the Cancer Center at Children's Hospital of Philadelphia
R. Nolan Townsend; Sandi See Tai, MD; Kim G. Johnson, MD
Daniela van Eickels, MD, PhD, MPH, the vice president and head of medical affairs for Bristol Myers Squibb’s Cell Therapy Organization
Paul Melmeyer, MPP, the executive vice president of public policy & advocacy at MDA
© 2024 MJH Life Sciences

All rights reserved.